Study guide

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls

MRCP UK

Track your progress as you read

Finished sections get a check mark.

1 MRCP(UK) Part 1: Exam Overview, Blueprint & Strategy

1.1 Part 1 Format, Delivery and Fees 1.2 The Official Blueprint and Mark Allocation 1.3 Scaled Scoring, Attempt Limits and Best-of-Five Technique

2 Clinical Sciences: Cellular, Genetic & Molecular Medicine

2.1 Organelles, Cytoskeleton & Membrane Transport 2.2 Cell Cycle Control, Apoptosis & Cell Signalling 2.3 Mendelian & Non-Mendelian Inheritance 2.4 Trinucleotide Repeat Disorders & Chromosomal Abnormalities 2.5 Purine, Pyrimidine Metabolism & the Porphyrias 2.6 Glycogen, Lipid Storage & Amino Acid Disorders

3 Clinical Sciences: Anatomy, Physiology & Immunology

3.1 Clinical & Cross-Sectional Anatomy 3.2 Systemic Clinical Physiology & Homeostasis 3.3 Clinical Immunology & Hypersensitivity Reactions

4 Clinical Sciences: Statistics, Epidemiology & Trial Design

4.1 Study Designs & Evidence Hierarchy 4.2 Diagnostic Testing, Screening & Predictive Values 4.3 Statistical Analysis & Risk Quantification

5 Clinical Pharmacology, Therapeutics & Toxicology

5.1 Pharmacokinetics & Pharmacodynamics 5.2 Cytochrome P450 Systems & High-Risk Drug Interactions 5.3 Adverse Drug Reactions & Therapeutic Drug Monitoring 5.4 Paracetamol & Salicylate Poisoning 5.5 Toxidromes, Antidotes, Carbon Monoxide & Toxic Alcohols

6 Cardiology: Coronary Artery Disease & Heart Failure

6.1 Acute Coronary Syndromes & Myocardial Infarction 6.2 Heart Failure & Cardiomyopathies 6.3 Cardiac Assessment & ECG Interpretation

7 Cardiology: Arrhythmias, Valvular & Pericardial Disease

7.1 Atrial Fibrillation, Narrow & Broad Complex Tachycardias 7.2 Bradyarrhythmias, Conduction Block & Antiarrhythmic Drugs 7.3 Valvular Heart Disease & Murmur Interpretation 7.4 Infective Endocarditis 7.5 Pericardial & Acute Aortic Diseases

8 Respiratory Medicine: Airway & Parenchymal Lung Disease

8.1 Asthma: Diagnosis, Chronic Management & Acute Attacks 8.2 COPD: GOLD Staging, Stable Management, Exacerbations & NIV 8.3 Interstitial Lung Disease & Sarcoidosis 8.4 Respiratory Infections & Bronchiectasis

9 Respiratory Medicine: Vascular, Pleural & Sleep Disorders

9.1 Venous Thromboembolism & Pulmonary Embolism 9.2 Pleural Effusion & Pneumothorax 9.3 Respiratory Failure & Sleep-Disordered Breathing

10 Gastroenterology: Luminal Gastrointestinal Disease

10.1 GORD, Barrett's Oesophagus & Oesophageal Motility Disorders 10.2 Peptic Ulcer Disease, Helicobacter pylori & Zollinger-Ellison Syndrome 10.3 Crohn's Disease, Ulcerative Colitis & Extraintestinal Manifestations 10.4 IBD Medical Therapy, Coeliac Disease & Malabsorption 10.5 Acute Upper Gastrointestinal Bleeding: Risk Scores, Ulcer & Variceal Haemorrhage 10.6 Lower Gastrointestinal Disorders & Colonic Neoplasia

11 Gastroenterology: Liver, Biliary & Pancreatic Disease

11.1 Viral Hepatitis A to E 11.2 Autoimmune Hepatitis & Metabolic Liver Disease 11.3 Cirrhosis & Complications of Portal Hypertension 11.4 Cholestatic Liver Disease: PBC and PSC 11.5 Gallstone Disease, Biliary Sepsis & Pancreatitis

12 Endocrinology & Diabetes: Diabetes & Thyroid

12.1 Diabetes: Diagnostic Thresholds, Classification & Pathophysiology 12.2 NICE-Directed Type 2 Therapy & Microvascular Complications 12.3 Acute Diabetic Emergencies (DKA & HHS) 12.4 Thyrotoxicosis, Thyroiditis & Management of Hyperthyroidism 12.5 Hypothyroidism, Subclinical Disease & Thyroid Nodules

13 Endocrinology & Diabetes: Adrenal, Pituitary & Calcium

13.1 Hypopituitarism, Pituitary Apoplexy & Hyperprolactinaemia 13.2 Acromegaly, Diabetes Insipidus & SIADH 13.3 Cushing's Syndrome: Aetiology, Screening & Localisation 13.4 Adrenal Insufficiency & Endocrine Hypertension 13.5 Calcium Regulation & Hypercalcaemia 13.6 Hypocalcaemia & Metabolic Bone Disease

14 Renal Medicine: AKI, Glomerular & Tubulointerstitial Disease

14.1 Acute Kidney Injury & Chronic Kidney Disease 14.2 Nephrotic and Nephritic Syndromes & Primary Glomerular Disease 14.3 Rapidly Progressive Glomerulonephritis 14.4 Tubulointerstitial & Inherited Renal Diseases

15 Renal Medicine: Fluid, Electrolytes & Acid-Base Balance

15.1 Sodium & Water Disorders 15.2 Potassium, Magnesium & Phosphate Disorders 15.3 Acid-Base Disorders & Blood Gas Analysis

16 Neurology: Cerebrovascular, Headache & Demyelinating Disease

16.1 Stroke Classification, Brainstem Syndromes & Hyperacute Reperfusion 16.2 Secondary Prevention, TIA, Carotid Surgery & Intracranial Haemorrhage 16.3 Headache Disorders & Cranial Neuralgias 16.4 Multiple Sclerosis & Central Demyelinating Diseases

17 Neurology: Epilepsy, Movement Disorders & Neuromuscular Disease

17.1 Epilepsy & Acute Seizures 17.2 Movement Disorders & Cognitive Impairment 17.3 Neuromuscular Junction & Peripheral Nerve Disorders

18 Rheumatology: Inflammatory Arthritis & Connective Tissue Disease

18.1 Rheumatoid Arthritis: Pathophysiology, Clinical Features & Diagnosis 18.2 DMARDs, Biologics & Their Toxicities 18.3 Seronegative Spondyloarthropathies 18.4 Systemic Lupus Erythematosus & Drug-Induced Lupus 18.5 Systemic Sclerosis & Scleroderma Renal Crisis 18.6 Sjogren's Syndrome & Inflammatory Myopathies

19 Rheumatology: Systemic Vasculitis & Crystal Arthropathy

19.1 Vasculitis Classification, Large and Medium Vessel Disease 19.2 ANCA-Associated and Immune Complex Small Vessel Vasculitis 19.3 Gout & Calcium Pyrophosphate Deposition Disease

20 Infectious Diseases & Tropical Medicine

20.1 Sepsis-3 Definitions & the Sepsis Six 20.2 Bacterial Meningitis, CSF Interpretation & Toxic Shock Syndrome 20.3 Tuberculosis: Pathogenesis & Clinical Manifestations 20.4 Tuberculosis: Diagnosis & Anti-Tuberculous Therapy 20.5 HIV Infection & Opportunistic Diseases 20.6 Malaria: Species, Life Cycle & Severe Disease 20.7 Enteric Fever, Arboviral Infection & Tissue Parasites

21 Haematology: Anaemias & Red Cell Disorders

21.1 MCV-Based Diagnostic Approach to Anaemia 21.2 Haemolytic and Autoimmune Haemolytic Anaemias 21.3 Membranopathies, Enzymopathies, PNH & Sickle Cell Disease

22 Haematology: Malignancy, Coagulation & Transfusion Medicine

22.1 Acute Leukaemias 22.2 Chronic Leukaemias & Myeloproliferative Neoplasms 22.3 Lymphomas & Plasma Cell Dyscrasias 22.4 Coagulation Cascade & Inherited Bleeding Disorders 22.5 Thrombocytopenia & Thrombotic Microangiopathies 22.6 Transfusion Products & Acute Transfusion Reactions

23 Psychiatry in General Medicine

23.1 Mood & Psychotic Disorders in Medical Patients 23.2 Psychiatric Emergencies & Substance Misuse 23.3 Mental Capacity & UK Mental Health Law

24 Geriatric Medicine

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls 24.2 Polypharmacy, Deprescribing & Pressure Ulcers

25 Dermatology

25.1 Inflammatory Skin Disease, Immunobullous Disorders & Severe Drug Eruptions 25.2 Cutaneous Malignancy

26 Oncology & Palliative Medicine

26.1 Neutropenic Sepsis, Spinal Cord Compression & SVC Obstruction 26.2 Hypercalcaemia of Malignancy & Tumour Lysis Syndrome 26.3 Palliative Care & End-of-Life Symptom Control

27 Medical Ophthalmology

27.1 The Acute Red Eye & Sudden Painless Visual Loss 27.2 Retinopathy in Systemic Disease

24.1 Comprehensive Geriatric Assessment, Frailty, Delirium & Falls

Key Takeaways Explain This Topic AI

Hypoactive delirium is more common and more often missed than hyperactive delirium, and carries a worse prognosis.

Delirium is managed by identifying and treating the precipitant with non-pharmacological measures first; antipsychotics are reserved for severe distress or risk and are avoided in Parkinson's disease and Lewy body dementia.

Orthostatic hypotension is a fall of at least 20 mmHg systolic or 10 mmHg diastolic within three minutes of standing.

Last updated: September 2026

Geriatric medicine forms a central pillar of acute internal medical practice in the NHS. In MRCP(UK) Part 1, candidates are tested extensively on the core domains of Comprehensive Geriatric Assessment (CGA), the clinical quantification of frailty, the acute diagnosis and protocolized management of delirium, multifactorial falls risk assessment, the pharmacology of safe prescribing in polypharmacy, and pressure injury classification.

  • 1. Comprehensive Geriatric Assessment (CGA) & Frailty
  • Comprehensive Geriatric Assessment (CGA)

CGA is defined as a multidimensional, interdisciplinary diagnostic and therapeutic process designed to determine an older person's medical, psychological, functional, and environmental capabilities and limitations, formulating a coordinated, personalized care and follow-up plan.

Evidence Base: Landmark Cochrane reviews demonstrate that hospitalised older adults undergoing formal CGA have a significantly higher likelihood of surviving and being discharged alive to their own homes (reduced institutionalisation), with reduced 30-day readmissions and improved functional independence compared to standard general medical care.

The Five Core CGA Domains:

Medical Assessment: Multimorbidity, disease severity, nutritional screening (Malnutrition Universal Screening Tool [MUST]), chronic pain, sensory impairment (vision, hearing), and structured medication review (deprescribing).

Psychological & Cognitive Assessment: Cognitive screening (4AT, Mini-Mental State Examination [MMSE], Montreal Cognitive Assessment [MoCA]), delirium assessment, and mood screening (Geriatric Depression Scale [GDS-15]).

Functional Capacity:

Basic Activities of Daily Living (BADLs / Barthel Index): Fundamental self-care tasks (feeding, bathing, grooming, dressing, toileting, continence, bed/chair transfers, and level walking).

Instrumental Activities of Daily Living (iADLs / Lawton-Brody Scale): Complex cognitive-motor activities necessary for independent community living (managing finances, shopping, food preparation, housekeeping, laundry, telephone usage, managing medications, and utilizing public transport). Impairment in iADLs characteristically predates loss of BADLs.

Social Assessment: Informal caregiver network, caregiver strain/burnout, formal statutory social care packages, eligibility for NHS Continuing Healthcare (CHC), and durable advance care planning.

Environmental Assessment: Home safety evaluation, trip hazards, access steps, lighting, grab rails, walking aids, stairlifts, telecare pendants, and ambient heating.

Clinical Frailty Scale (Rockwood CFS)

Frailty is a distinct biological syndrome characterized by a cumulative decline in physiological reserve across multiple organ systems, resulting in heightened vulnerability to disproportionate decompensation following minor physiological stressors (e.g. minor UTI, constipation, medication change). Rockwood Clinical Frailty Scale (CFS 1–9)

  • │
  • ├── CFS 1 (Very Fit): Robust, active, energetic; exercises regularly
  • ├── CFS 2 (Fit): No active disease; less fit than Category 1; exercises seasonally
  • ├── CFS 3 (Managing Well): Medical problems controlled; not regularly active beyond walking
  • ├── CFS 4 (Living with Very Mild Frailty): Not dependent; symptoms limit activities; "slowed down"

├── CFS 5 (Living with Mild Frailty): Evident slowing; needs help in high-order iADLs (finances, transport, meds)

├── CFS 6 (Living with Moderate Frailty): Needs help with all outside activities and some BADLs (bathing, dressing)

  • ├── CFS 7 (Living with Severe Frailty): Completely dependent for personal care (BADLs); clinically stable
  • ├── CFS 8 (Living with Very Severe Frailty): Completely dependent; approaching end-of-life from minor illness
  • └── CFS 9 (Terminally Ill): Life expectancy <6 months; not otherwise living with severe frailty

Clinical Significance:

A CFS score ≥5 defines established clinical frailty .

CFS is evaluated based on the patient's baseline functional state 2 weeks prior to acute hospital admission (avoid scoring frailty during an acute delirium or decompensated illness).

CFS independently predicts in-hospital mortality, institutionalisation, prolonged hospital length of stay, delirium risk, and poor post-operative outcomes.

2. Delirium (Acute Confusional State)

Delirium is an acute, neuropsychiatric syndrome characterized by concurrent disturbances of consciousness, attention, perception, and circadian rhythms, affecting 20–30% of acute medical inpatients.

Pathophysiology & Clinical Subtypes

Pathophysiology: Neuroinflammation driven by peripheral pro-inflammatory cytokines (IL-1, IL-6, TNF-α) disrupting the blood-brain barrier, central cholinergic deficiency, and relative dopaminergic and glutamatergic excess.

Clinical Characteristics: Acute onset (hours to days), fluctuating course throughout the day (often worsening in the evening: 'sundowning'), marked inattention (inability to focus, sustain, or shift attention), disorganized thinking, and perceptual hallucinations.

Delirium Subtype Clinical Prevalence Cardinal Phenotypic Features Clinical Pitfalls & Prognosis

Hypoactive Delirium 50–60% (Most common) Lethargy, psychomotor slowing, apathy, drowsiness, quiet confusion, poverty of spontaneous speech Frequently missed or misdiagnosed as depression, dementia, or fatigue. Associated with the highest mortality, greatest risk of aspiration, pressure ulcers, and poorest functional recovery.

Hyperactive Delirium 20–25% Psychomotor agitation, restlessness, emotional lability, irritability, combativeness, overt visual/auditory hallucinations Readily recognized; often triggers inappropriate pharmacological restraint. Better overall survival than hypoactive.

Mixed Delirium 20–25% Rapid, unpredictable fluctuation between hyperactive agitation and hypoactive lethargy Management must avoid over-sedation during hyperactive phases that worsens hypoactive stupor.

Diagnostic Screening: The 4AT Rapid Tool

The 4AT is the validated, NICE-recommended bedside screening instrument for acute delirium (sensitivity 88%, specificity 88%):

Alertness: Normal (0), Mild sleepiness <10 s after waking (0), Clearly abnormal (4).

AMT4 (Age, Date of Birth, Place, Current Year): No errors (0), 1 error (1), 2+ errors or untestable (2).

Attention (Months of the year backwards): ≥7 months correct (0), Starts but <7 correct / refuses (1), Untestable (2).

Acute Change or Fluctuating Course: Evidence of acute alteration in mental status over past 2 weeks (4).

Scoring Interpretation: ≥4 = Probable Delirium ; 1–3 = Possible cognitive impairment; 0 = Delirium unlikely.

Precipitants: The "PINCH ME" Mnemonic

Delirium is rarely caused by a single insult; it typically represents the collision of underlying vulnerability (dementia, advanced age, sensory loss) and acute precipitants:

P — Pain: Unrecognized surgical abdomen, occult fractures (e.g. pubic rami, femoral neck), severe arthritis, urinary retention.

I — Infection / Sepsis: Lower respiratory tract infection, urinary tract infection, cellulitis, intra-abdominal sepsis, line infections.

N — Nutrition: Malnutrition, severe dehydration, vitamin deficiencies (B12, folate, thiamine).

C — Constipation: Severe faecal impaction causing discomfort and autonomic distress.

H — Hydration / Acute Urinary Retention: Bladder distension, catheter blockage, severe hypovolaemia, prerenal acute kidney injury.

M — Medication Changes: High-risk drug initiation, dose escalation, or abrupt drug withdrawal (anticholinergics, sedatives, benzodiazepines, opiates, corticosteroids, antiparkinsonian drugs).

E — Electrolytes & Metabolic Derangements: Hyponatraemia, hypernatraemia, hypercalcaemia, hypoglycaemia, uremia, hepatic encephalopathy, hypoxaemia, hypercapnia, myocardial ischaemia.

Management Principles

Non-Pharmacological Measures (FIRST-LINE & MAINSTAY): Reorientation cues (visible wall clocks, calendars), consistent nursing staff, maintaining sleep-wake cycles (quiet nights, natural daytime lighting), ensuring sensory aids (glasses, working hearing aids) are immediately restored, early mobilization, removing unnecessary catheters and cannulas, and encouragement of family presence.

Pharmacological Intervention (LAST RESORT ONLY):

Reserved strictly for patients exhibiting severe intractable distress, terrifying hallucinations, or imminent physical danger to themselves or clinical staff that fails non-pharmacological calming.

Haloperidol (0.5 mg orally or IM, max 1–2 mg in 24 hours). Administer lowest effective dose for shortest possible duration.

CRITICAL CONTRAINDICATION: Haloperidol and all dopamine D2 receptor antagonists are ABSOLUTELY CONTRAINDICATED in patients with Parkinson's Disease or Dementia with Lewy Bodies (DLB) . They can precipitate irreversible, catastrophic motor rigidity, acute parkinsonian crisis, or fatal Neuroleptic Malignant Syndrome. In DLB or Parkinson's disease, if sedation is vital, low-dose oral lorazepam (0.5 mg) or quetiapine (12.5–25 mg) is used.

3. Falls in the Older Person & Orthostatic Hypotension

Falls are the leading cause of accidental injury and trauma-related death in patients over 65. In the UK, one-third of community-dwelling individuals over 65 experience a fall annually.

Multifactorial Falls Risk Assessment (NICE CG161)

Every older inpatient presenting with a fall must undergo a structured multifactorial assessment:

Gait and Balance Evaluation: The Timed Up and Go (TUG) Test : The patient rises from a standard armchair, walks 3 metres, turns, walks back, and sits down. A time >12–15 seconds indicates impaired mobility and significantly increased fall risk .

Polypharmacy & Medication Rationalisation: Identifying fall-risk increasing drugs (FRIDs: sedatives, hypnotics, antipsychotics, antidepressants, antihypertensives, anticholinergics).

Sensory & Visual Testing: Refraction errors, cataracts, glaucoma, peripheral diabetic sensory neuropathy.

Environmental Hazards: Clutter, loose rugs, inappropriate footwear, inadequate lighting.

Cardiovascular Syncope vs Mechanical Fall: Detailed collateral history, 12-lead ECG, telemetry, echocardiography, carotid sinus massage (if carotid sinus hypersensitivity suspected).

Orthostatic (Postural) Hypotension

Diagnostic Definition: A sustained drop in Systolic Blood Pressure (SBP) ≥20 mmHg and/or Diastolic Blood Pressure (DBP) ≥10 mmHg within 3 minutes of standing from a supine/sitting position (or an SBP drop ≥30 mmHg in patients with baseline supine systolic hypertension ≥160 mmHg).

Pathophysiology: Age-related baroreceptor desensitization, blunted sympathetic outflow, decreased vascular compliance, venous pooling, autonomic neuropathy, and volume contraction.

Management Strategy:

Step 1: Non-Pharmacological / Conservative (First-line):

Deprescribing culprit medications: alpha-blockers (e.g. tamsulosin, doxazosin), calcium channel blockers, nitrates, diuretics, ACE inhibitors.

Gradual positional changes ("sit on the edge of the bed before standing").

Physical counter-manoeuvres: leg-crossing, thigh contraction, squatting, buttock clenching during standing.

Elevation of the head of the bed by 10–15° (reduces renal arterial pressure overnight, suppressing nocturnal pressure natriuresis and maintaining intravascular volume).

Oral hydration (2.0–2.5 L/day) and liberalized dietary sodium.

Waist-high graded compression hosiery or abdominal binders.

Step 2: Pharmacological Therapy:

Fludrocortisone: Synthetic mineralocorticoid (50–200 mcg orally once daily). Promotes renal distal tubular sodium retention, expanding intravascular blood volume. Monitoring: Hypokalaemia, supine hypertension, peripheral oedema, and worsening heart failure.

Midodrine: Selective peripheral α1-adrenergic receptor agonist (2.5–10 mg orally three times daily). Induces peripheral arteriolar and venous vasoconstriction, boosting venous return. Caution: Administer during daytime hours; avoid dosing within 4 hours of bedtime to prevent severe supine hypertension .